S&P Futures
3,981.25 +10.75 (+0.27%) Dow Futures
32,357.00 +99.00 (+0.31%) Nasdaq Futures
12,734.25 +27.25 (+0.21%) Russell 2000 Futures
1,750.40 +9.40 (+0.54%) Crude Oil
70.10 -0.80 (-1.13%) Gold
1,969.60 +20.00 (+1.03%)
After hours:
- Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 01, 2023--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares of its common stock to two new employees. The inducement stock options have a grant date of February 28, 2023 and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).
- InvestorPlace
6 F-Rated Penny Stocks Not Worth Your Dime
As the adage goes, “where there’s risk, there’s reward.” Unfortunately, this is not universal when it comes to penny stocks. While there are plenty of stocks in “penny territory” (under $5 per share) that are strong opportunities, there are also scores of low-priced names best characterized as penny stocks to sell. When it comes to risk/reward, names in this category offer a lot of former, but an inadequate amount of latter. For the most part, stocks at this price level are one of two things. Th
- Business Wire
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan
SAN DIEGO, January 06, 2023--Biocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc., as its financial advisor to assist in this process.
